GITNUXREPORT 2025

Pharma Industry Statistics

Pharma industry rapidly evolves with innovation, digitalization, and market growth.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

The global pharmaceutical market is projected to reach a value of $1.5 trillion by 2023

Statistic 2

The United States accounts for approximately 48% of the global pharmaceutical market

Statistic 3

Around 60% of new drugs approved by FDA in 2022 were for treating rare diseases

Statistic 4

The biosimilars market is expected to grow at a CAGR of 10% between 2022 and 2027

Statistic 5

The top 10 pharma companies accounted for over 45% of global prescription drug sales in 2022

Statistic 6

The number of approved biologic drugs increased by 18% from 2019 to 2022

Statistic 7

The global vaccine market is valued at approximately $49 billion in 2023, with a projected CAGR of 7% through 2028

Statistic 8

The top therapeutic areas by revenue in 2022 were oncology, immunology, and cardiovascular diseases

Statistic 9

The pharmaceutical industry accounts for about 4% of total global healthcare spending

Statistic 10

Global pharmaceutical employment is estimated at over 6 million jobs worldwide

Statistic 11

The percentage of orphan drugs (for rare diseases) approved by FDA has increased from 12% in 2015 to over 25% in 2022

Statistic 12

In 2022, the global clinical trials market was valued at approximately $65 billion, projected to grow at a CAGR of 5.7% through 2030

Statistic 13

Generic drugs make up around 85% of prescriptions filled in the US, accounting for less than 20% of total pharma sales revenue

Statistic 14

The top biotechnology companies by revenue in 2022 included Gilead Sciences, Biogen, and Regeneron, with revenues exceeding $20 billion each

Statistic 15

Investments in digital health startups related to pharma reached over $12 billion globally in 2022

Statistic 16

The global stem cell therapy market is expected to grow from $2.6 billion in 2022 to over $13 billion by 2027, at a CAGR of 37%

Statistic 17

Approximately 70% of revenue for some pharma companies now comes from oncology drugs

Statistic 18

The global market for over-the-counter (OTC) drugs is valued at approximately $132 billion in 2023, with a CAGR of around 4%

Statistic 19

The percentage of digital/computerized clinical trial data management systems used in pharma increased from 30% in 2019 to over 75% in 2023

Statistic 20

The amount spent annually on Marketing and Sales by major pharma companies exceeds $3 billion per company

Statistic 21

The global anti-aging pharmaceuticals market is projected to reach $72 billion by 2028, growing at a CAGR of 8%

Statistic 22

The pharmaceutical industry's environmental impact includes generating over 1 million tons of waste annually

Statistic 23

Pharmaceutical supply chain disruptions during 2020-2022 led to an estimated $50 billion in lost revenue globally

Statistic 24

The global pharmaceutical logistics market is projected to reach $150 billion by 2027, growing at a CAGR of 7.5%

Statistic 25

The use of blockchain technology in pharmaceutical supply chains is expected to grow at a CAGR of 42% from 2022 to 2028

Statistic 26

Elderly populations worldwide are expected to increase by 48% between 2020 and 2050, driving demand for pharma solutions for age-related diseases

Statistic 27

The global immunotherapy market was valued at approximately $137 billion in 2022, expected to grow at a CAGR of 11% through 2028

Statistic 28

The global market for personalized medicine is valued at around $149 billion in 2023 and is expected to grow at a CAGR of 11% through 2030

Statistic 29

The top five Latin American countries for pharma growth in 2023 are Brazil, Mexico, Argentina, Colombia, and Chile, with market growth rates averaging 5-8%

Statistic 30

The global veterinary pharmaceuticals market is projected to reach $21 billion by 2027, growing at a CAGR of 5.8%

Statistic 31

The revenue from specialty drugs, which include biotech and rare disease treatments, accounts for approximately 50% of total pharma sales in developed markets

Statistic 32

The number of global generic drug approvals increased by 15% in 2022 compared to 2021, indicating an expanding generic market

Statistic 33

The COVID-19 pandemic led to a 25% increase in the adoption of telemedicine in healthcare, including pharma-related consultations

Statistic 34

The pharmaceutical patent cliff is expected to reach its peak between 2024 and 2026, with about $40 billion worth of patents expiring annually

Statistic 35

The global inhaler devices market is projected to reach $22 billion by 2028, growing at a CAGR of 6%

Statistic 36

The percentage of pharma companies investing in sustainability initiatives increased from 20% in 2019 to over 60% in 2023, reflecting industry commitments to environmental responsibility

Statistic 37

Access to essential medicines remains a challenge in low-income countries, with only 60% of the population having reliable access

Statistic 38

The percentage of drugs approved via accelerated approval pathways increased from 15% in 2015 to 25% in 2022

Statistic 39

The number of FDA drug approvals in 2022 was 50, up from 45 in 2021, indicating a trend toward faster approvals

Statistic 40

The use of real-world evidence (RWE) in pharma regulatory decisions increased by over 70% from 2019 to 2022

Statistic 41

In 2022, pharmaceutical R&D expenditure worldwide was approximately $219 billion

Statistic 42

The average cost to develop a new drug is estimated at $2.6 billion

Statistic 43

Approximately 30% of pharmaceutical revenue is spent on R&D

Statistic 44

The COVID-19 pandemic accelerated biotech innovation with over 50 new vaccines developed in record time

Statistic 45

Approximately 80% of new drugs launched fail during clinical trials

Statistic 46

Female representation in clinical trials increased from 36% in 2015 to 42% in 2022

Statistic 47

The average age of a new drug candidate entering clinical trials is around 36 months

Statistic 48

The most common therapeutic class for pharma innovation in 2023 is gene therapy, with over 150 products in development pipeline

Statistic 49

The number of pharmaceutical patents granted globally increased by 12% from 2021 to 2022

Statistic 50

Approximately 25% of all pharma R&D budgets now go toward personalized medicine development

Statistic 51

Major pharma companies have reduced their drug approval times from an average of 60 months to around 36 months over the past decade

Statistic 52

The number of orphan drug designations had increased by over 200% between 2010 and 2022

Statistic 53

Over 65% of pharma companies are investing in artificial intelligence to streamline drug discovery processes

Statistic 54

The median time from drug discovery to market launch has decreased from 84 months in 2010 to about 64 months in 2022

Statistic 55

In 2023, over 3,000 clinical trials were ongoing for COVID-19 treatments, with around 25% focused on oral therapeutics

Statistic 56

The average success rate for a drug in Phase III clinical trials is approximately 60%

Statistic 57

Approximately 50% of new drug approvals in 2022 were based on breakthrough therapy designation, indicating a focus on innovative treatments

Statistic 58

The R&D pipeline for cell and gene therapies includes over 2,000 ongoing projects worldwide in 2023, representing significant sector growth

Statistic 59

Digital transformation in pharma is expected to save the industry over $150 billion annually by 2030

Statistic 60

Over 40% of pharma companies have adopted cloud computing for data storage and analysis, aiming to enhance collaboration and efficiency

Slide 1 of 60

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

The global pharmaceutical market is projected to reach a value of $1.5 trillion by 2023
The United States accounts for approximately 48% of the global pharmaceutical market
In 2022, pharmaceutical R&D expenditure worldwide was approximately $219 billion
The average cost to develop a new drug is estimated at $2.6 billion
Approximately 30% of pharmaceutical revenue is spent on R&D
The COVID-19 pandemic accelerated biotech innovation with over 50 new vaccines developed in record time
Around 60% of new drugs approved by FDA in 2022 were for treating rare diseases
The biosimilars market is expected to grow at a CAGR of 10% between 2022 and 2027
The top 10 pharma companies accounted for over 45% of global prescription drug sales in 2022
Approximately 80% of new drugs launched fail during clinical trials
Access to essential medicines remains a challenge in low-income countries, with only 60% of the population having reliable access
The number of approved biologic drugs increased by 18% from 2019 to 2022
Female representation in clinical trials increased from 36% in 2015 to 42% in 2022

The pharmaceutical industry is rapidly evolving into a multi-trillion-dollar, innovation-driven sector, fueled by breakthroughs in gene therapy, personalized medicine, and biotech innovation, while simultaneously grappling with challenges such as high R&D costs, supply chain disruptions, and unequal access to essential medicines worldwide.

Market Size and Revenue Trends

The global pharmaceutical market is projected to reach a value of $1.5 trillion by 2023
The United States accounts for approximately 48% of the global pharmaceutical market
Around 60% of new drugs approved by FDA in 2022 were for treating rare diseases
The biosimilars market is expected to grow at a CAGR of 10% between 2022 and 2027
The top 10 pharma companies accounted for over 45% of global prescription drug sales in 2022
The number of approved biologic drugs increased by 18% from 2019 to 2022
The global vaccine market is valued at approximately $49 billion in 2023, with a projected CAGR of 7% through 2028
The top therapeutic areas by revenue in 2022 were oncology, immunology, and cardiovascular diseases
The pharmaceutical industry accounts for about 4% of total global healthcare spending
Global pharmaceutical employment is estimated at over 6 million jobs worldwide
The percentage of orphan drugs (for rare diseases) approved by FDA has increased from 12% in 2015 to over 25% in 2022
In 2022, the global clinical trials market was valued at approximately $65 billion, projected to grow at a CAGR of 5.7% through 2030
Generic drugs make up around 85% of prescriptions filled in the US, accounting for less than 20% of total pharma sales revenue
The top biotechnology companies by revenue in 2022 included Gilead Sciences, Biogen, and Regeneron, with revenues exceeding $20 billion each
Investments in digital health startups related to pharma reached over $12 billion globally in 2022
The global stem cell therapy market is expected to grow from $2.6 billion in 2022 to over $13 billion by 2027, at a CAGR of 37%
Approximately 70% of revenue for some pharma companies now comes from oncology drugs
The global market for over-the-counter (OTC) drugs is valued at approximately $132 billion in 2023, with a CAGR of around 4%
The percentage of digital/computerized clinical trial data management systems used in pharma increased from 30% in 2019 to over 75% in 2023
The amount spent annually on Marketing and Sales by major pharma companies exceeds $3 billion per company
The global anti-aging pharmaceuticals market is projected to reach $72 billion by 2028, growing at a CAGR of 8%
The pharmaceutical industry's environmental impact includes generating over 1 million tons of waste annually
Pharmaceutical supply chain disruptions during 2020-2022 led to an estimated $50 billion in lost revenue globally
The global pharmaceutical logistics market is projected to reach $150 billion by 2027, growing at a CAGR of 7.5%
The use of blockchain technology in pharmaceutical supply chains is expected to grow at a CAGR of 42% from 2022 to 2028
Elderly populations worldwide are expected to increase by 48% between 2020 and 2050, driving demand for pharma solutions for age-related diseases
The global immunotherapy market was valued at approximately $137 billion in 2022, expected to grow at a CAGR of 11% through 2028
The global market for personalized medicine is valued at around $149 billion in 2023 and is expected to grow at a CAGR of 11% through 2030
The top five Latin American countries for pharma growth in 2023 are Brazil, Mexico, Argentina, Colombia, and Chile, with market growth rates averaging 5-8%
The global veterinary pharmaceuticals market is projected to reach $21 billion by 2027, growing at a CAGR of 5.8%
The revenue from specialty drugs, which include biotech and rare disease treatments, accounts for approximately 50% of total pharma sales in developed markets
The number of global generic drug approvals increased by 15% in 2022 compared to 2021, indicating an expanding generic market
The COVID-19 pandemic led to a 25% increase in the adoption of telemedicine in healthcare, including pharma-related consultations
The pharmaceutical patent cliff is expected to reach its peak between 2024 and 2026, with about $40 billion worth of patents expiring annually
The global inhaler devices market is projected to reach $22 billion by 2028, growing at a CAGR of 6%
The percentage of pharma companies investing in sustainability initiatives increased from 20% in 2019 to over 60% in 2023, reflecting industry commitments to environmental responsibility

Market Size and Revenue Trends Interpretation

With the pharmaceutical industry ramping up to a staggering $1.5 trillion globally—dominated by the U.S. and fueled by blockbuster oncology, personalized, and biologic drugs—while embracing digital health and sustainability, it's clear that pharma's future is both a high-stakes game of innovation and a delicate balancing act of environmental and economic responsibility.

Regulatory and Access Challenges

Access to essential medicines remains a challenge in low-income countries, with only 60% of the population having reliable access
The percentage of drugs approved via accelerated approval pathways increased from 15% in 2015 to 25% in 2022
The number of FDA drug approvals in 2022 was 50, up from 45 in 2021, indicating a trend toward faster approvals
The use of real-world evidence (RWE) in pharma regulatory decisions increased by over 70% from 2019 to 2022

Regulatory and Access Challenges Interpretation

While only 60% of low-income populations enjoy reliable access to essential medicines, the rising reliance on accelerated approvals and real-world evidence by regulators signals a fast-tracking of innovation—yet the challenge remains to ensure that robust treatment reaches those most in need.

Research and Development Insights

In 2022, pharmaceutical R&D expenditure worldwide was approximately $219 billion
The average cost to develop a new drug is estimated at $2.6 billion
Approximately 30% of pharmaceutical revenue is spent on R&D
The COVID-19 pandemic accelerated biotech innovation with over 50 new vaccines developed in record time
Approximately 80% of new drugs launched fail during clinical trials
Female representation in clinical trials increased from 36% in 2015 to 42% in 2022
The average age of a new drug candidate entering clinical trials is around 36 months
The most common therapeutic class for pharma innovation in 2023 is gene therapy, with over 150 products in development pipeline
The number of pharmaceutical patents granted globally increased by 12% from 2021 to 2022
Approximately 25% of all pharma R&D budgets now go toward personalized medicine development
Major pharma companies have reduced their drug approval times from an average of 60 months to around 36 months over the past decade
The number of orphan drug designations had increased by over 200% between 2010 and 2022
Over 65% of pharma companies are investing in artificial intelligence to streamline drug discovery processes
The median time from drug discovery to market launch has decreased from 84 months in 2010 to about 64 months in 2022
In 2023, over 3,000 clinical trials were ongoing for COVID-19 treatments, with around 25% focused on oral therapeutics
The average success rate for a drug in Phase III clinical trials is approximately 60%
Approximately 50% of new drug approvals in 2022 were based on breakthrough therapy designation, indicating a focus on innovative treatments
The R&D pipeline for cell and gene therapies includes over 2,000 ongoing projects worldwide in 2023, representing significant sector growth

Research and Development Insights Interpretation

While pharma's $219 billion R&D investment and a $2.6 billion average per drug underscore its relentless pursuit of innovation, the sobering reality that 80% of new drugs fail in trials reminds us that in this high-stakes game, breakthroughs are as hard-won as they are celebrated—yet with gene therapy, AI, and orphan drugs driving a 200% increase in designations, the sector's future is as promising as it is complex.

Technological Innovations and Digital Transformations

Digital transformation in pharma is expected to save the industry over $150 billion annually by 2030
Over 40% of pharma companies have adopted cloud computing for data storage and analysis, aiming to enhance collaboration and efficiency

Technological Innovations and Digital Transformations Interpretation

With digital transformation poised to save the pharma industry over $150 billion annually by 2030 and nearly half embracing cloud computing, the sector is on a clear trajectory from traditional pill-popping to data-driven innovation—or risk getting left behind in the digital dust.